No abstract available
MeSH terms
-
Antibodies, Monoclonal / adverse effects
-
Antibodies, Monoclonal / immunology
-
Antibodies, Monoclonal / therapeutic use*
-
Antigens, CD / immunology
-
Antineoplastic Agents / immunology
-
Antineoplastic Agents / pharmacology
-
Antineoplastic Agents / therapeutic use
-
Antineoplastic Combined Chemotherapy Protocols
-
CTLA-4 Antigen
-
Clinical Trials as Topic
-
Drug Approval*
-
Humans
-
Immunotherapy / methods
-
Ipilimumab
-
Melanoma / drug therapy*
-
Melanoma / genetics
-
Melanoma / immunology
-
Melanoma / pathology
-
Proto-Oncogene Proteins B-raf / antagonists & inhibitors
-
Proto-Oncogene Proteins B-raf / genetics
-
Survival Analysis
-
United States
-
United States Food and Drug Administration
Substances
-
Antibodies, Monoclonal
-
Antigens, CD
-
Antineoplastic Agents
-
CTLA-4 Antigen
-
CTLA4 protein, human
-
Ipilimumab
-
BRAF protein, human
-
Proto-Oncogene Proteins B-raf